<DOC>
	<DOCNO>NCT01087658</DOCNO>
	<brief_summary>Primary Objective : To assess benefit glutamine add calcium-magnesium occurrence grade 2 , 3 4 peripheral sensory neuropathy ( PSN ) relate oxaliplatin National Cancer Institute-Common Terminology Criteria Adverse Event ( NCI-CTCAE ) scale take account time start oxaliplatin first event occur . Secondary Objective : To determine cumulative dose oxaliplatin time first occurrence grade 2 , 3 4 PSN . To determine incidence dose-reductions , dose-delays discontinuation oxaliplatin due PSN grade 3 4 . To assess effect glutamine add calcium-magnesium patients-reported outcome use Functional Assessment Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity 12 item questionnaire ( FACT/GOG NTX-12 ) subscale . To evaluate incidence diarrhea . To determine Progression Free Survival ( PFS ) metastatic patient .</brief_summary>
	<brief_title>Oral Glutamine Prevention Oxaliplatin-induced Neurotoxicity</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Inclusion criterion : 1 . Histologically cytologically proven adenocarcinoma colon rectum . 2 . Disease either adjuvant 1st line metastatic setting . 3 . Eastern Cooperation Oncology Group ( ECOG ) performance status inferior equal 2 . 4 . At least 4 week follow major surgical procedure ( ) recovery surgical sequela . 5 . Electrocardiogram ( ECG ) acute recent change within limit normal range , present abnormality contraindicate propose chemotherapy . 6 . Adequate liver kidney function : Total bilirubin inferior 1.5 ULN Serum creatinine inferior 150 umol/L Creatinine clearance ( ClCr ) superior 45 mL/min ALT/AST inferior 3 ULN Alkaline phosphatase inferior equal 2 ULN , unless liver metastasis present documented baseline Computed Tomography ( CT ) Magnetic Resonance Imaging ( MRI ) scan ( inferior equal 3,5 ULN case ) . 7 . Adequate hematological function : Neutrophils superior equal 1.5 x 109/L Platelet count superior equal 100 x 109/L Hemoglobin superior 9 g/dL Exclusion criterion : 1 . Any condition past medical history contraindicates treatment oxaliplatin , 5fluorouracil ( 5FU ) , leucovorin ( LV ) capecitabine report approve labeling information . 2 . Previous oxaliplatinbased chemotherapy . 3 . Previous current diagnosis PSN . 4 . Concomitant treatment drugs/ingredients report potential activity prevent PSN : carbamazepine , amitriptyline , gabapentin , phenytoin , glutathione , alphalipoic acid , celecoxib , amifostine , venlafaxine , vitamin B1 ( thiamine ) , B6 ( pyridoxine ) . 5 . History know allergy oxaliplatin platinum agent , 5FU , LV capecitabine . 6 . History know allergy glutamine calciummagnesium . 7 . Participation another clinical trial investigational drug within 30 day prior study screen . 8 . Uncontrolled intercurrent illness : e.g . high blood pressure , unstable angina , symptomatic congestive heart failure ( New York Heart Association Classification III IV ) , 9 . Serious cardiac arrhythmia , diabetes , active infection . 10 . Concurrent active cancer originate primary site colon rectum . 11 . Presence symptom suggest brain metastasis . 12 . Patients pregnant breastfeed 13 . Patients ( male female ) reproductive potential implementing accept effective method contraception 14 . For patient receive Bevacizumab : Bevacizumab contraindicate patient know hypersensitivity component product Chinese hamster ovary cell product recombinant human humanize antibodies The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>